Olipudase Alfa-Rpcp
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results.
Journal: Journal of inherited metabolic disease
Published: January 08, 2026
Regulatory news: Olipudase alfa-rpcp (Xenpozyme™) for treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients-FDA Approval summary.
Journal: Journal of inherited metabolic disease
Published: August 29, 2023
Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
Journal: Clinical drug investigation
Published: April 13, 2023
Olipudase Alfa-rpcp.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: October 18, 2022
Showing 1-5 of 5
Last Updated: 06/30/2026